The Moving Average Convergence Divergence (MACD) for PHMMF turned positive on December 09, 2024. Looking at past instances where PHMMF's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 184 cases where PHMMF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHMMF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.369) is normal, around the industry mean (14.664). PHMMF's P/E Ratio (1878.886) is considerably higher than the industry average of (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). Dividend Yield (0.009) settles around the average of (0.012) among similar stocks. P/S Ratio (8.039) is also within normal values, averaging (260.687).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FIJZX | 56.23 | 0.15 | +0.27% |
Fidelity Advisor Consumer Discret Z | |||
COGMX | 12.85 | 0.03 | +0.23% |
AXS Market Neutral Inv | |||
VVISX | 12.47 | N/A | N/A |
Vulcan Value Partners Small Cap Instl | |||
JEMGX | 9.80 | -0.03 | -0.31% |
JHancock Emerging Markets Equity R6 | |||
HGOAX | 61.63 | -0.57 | -0.92% |
Hartford Growth Opportunities A |
A.I.dvisor indicates that over the last year, PHMMF has been loosely correlated with DRUG. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PHMMF jumps, then DRUG could also see price increases.
Ticker / NAME | Correlation To PHMMF | 1D Price Change % | ||
---|---|---|---|---|
PHMMF | 100% | N/A | ||
DRUG - PHMMF | 42% Loosely correlated | +2.40% | ||
CSCI - PHMMF | 22% Poorly correlated | -0.85% | ||
KALV - PHMMF | 21% Poorly correlated | -3.35% | ||
ACAD - PHMMF | 21% Poorly correlated | +0.40% | ||
AVCTF - PHMMF | 20% Poorly correlated | N/A | ||
More |